Insider sales are small in absolute terms (0.075% of market cap) and occur after option exercises, indicative of post-vesting profit-taking rather than a bearish conviction signal. The cluster is amplified by recent dilutive offerings but does not independently suggest material adverse information. Monitor for any pre-announcement of AMT-130 BLA timing or trial data; upcoming Q3 2026 filing is the primary catalyst.
Drug in focus
QURE drug pipeline →AMT-130
▲ Bullish Named in this insider cluster- Impact
- Phase
- Phase 1/2 (pivotal for accelerated approval)
- Time to market
- BLA submission planned for Q3 2026; FDA accelerated approval decision likely 6-10 months after submission (potentially H1 2027)
- Next catalyst
- None dated
What to watchThe BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jul 6 $41.81entry
- T+1 · 4mo ago −1.08%α −1.95% · $41.36
- T+5 · 4mo ago +6.39%α +5.46% · $44.48
- T+20 · 4mo ago +0.91%α +1.32% · $42.19
- T+60 · due 7w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cluster of insider sales at uniQure following two recent $225M and $150M capital raises, with total open-market insider sales of ~$2.1M (0.075% of $2.8B market cap). Director Kaye Jack and CMO Abi-Saab Walid sold shares on June 30 after exercising low-strike options, and CEO Matthew Kapusta sold $1.44M on June 25. The sales are small relative to market cap but the timing, immediately after dilutive offerings and ahead of a pivotal BLA filing, raises optics concerns.
Key Financial Metrics
Key Facts
- Open-market insider sales total ~$2.09M across three insiders within 7 days.
- CEO Matthew Kapusta sold $1.44M worth of shares on June 25 at ~$50.02.
- Director Kaye Jack sold ~$1.0M total on June 30, with offsetting derivative exercises at $0-$20.18 strikes.
- CMO Walid Abi-Saab sold $1.39M total on June 30, including exercises of low-strike options.
- These sales follow a $225M public offering priced on June 23 at $45.50 (7.2% discount) and a $150M offering announced June 22.
- Offering proceeds are earmarked for AMT-130 (Huntington's gene therapy) BLA filing and commercialization.
- Total insider sales represent ~0.075% of market cap, below the 0.1% threshold for materiality.
- Non-cash derivative exercises on June 30 account for $552K in shares received at zero or low cost, all sold same-day.
- No 10b5-1 plan indicated; timing aligns with post-offering blackout window reopening.
Financial Impact
Total insider open-market sales of ~$2.09M (0.075% of market cap), combined with $375M in recent dilutive offerings that added ~7.8% share count dilution.
Risk Factors
- Insiders selling after option exercises could signal limited conviction in near-term stock upside post-offering dilution.
- CEO sale of $1.44M at $50 (above offering price of $45.50) may be purely liquidity-driven but timing is unfavorable.
- Concentration of sales on June 30, the same day for Kaye and Abi-Saab, suggests a shared blackout window reopening.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-QURE-1783060238191 |
Track record
38 reports on QURE
5 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Viewing Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers